Axogen, Inc. AXGN
We take great care to ensure that the data presented and summarized in this overview for Axogen, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AXGN
View all-
First Light Asset Management, LLC Edina, MN4.53MShares$78 Million7.55% of portfolio
-
Black Rock Inc. New York, NY3.25MShares$56 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.73MShares$47 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.51MShares$43.3 Million0.0% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.93MShares$33.3 Million0.03% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO1.63MShares$28 Million0.36% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT1.46MShares$25.1 Million1.23% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.43MShares$24.7 Million0.08% of portfolio
-
Assenagon Asset Management S.A.1.29MShares$22.2 Million0.04% of portfolio
-
State Street Corp Boston, MA1.12MShares$19.3 Million0.0% of portfolio
Latest Institutional Activity in AXGN
Top Purchases
Top Sells
About AXGN
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Insider Transactions at AXGN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 22
2025
|
William P. Burke Mr. Director |
SELL
Open market or private sale
|
Direct |
1,457
-93.58%
|
$26,226
$18.02 P/Share
|
|
Oct 06
2025
|
William P. Burke Mr. Director |
SELL
Open market or private sale
|
Direct |
736
-32.1%
|
$13,248
$18.0 P/Share
|
|
Oct 03
2025
|
William P. Burke Mr. Director |
SELL
Open market or private sale
|
Direct |
14,571
-86.4%
|
$262,278
$18.21 P/Share
|
|
Oct 03
2025
|
William P. Burke Mr. Director |
SELL
Open market or private sale
|
Indirect |
7,600
-100.0%
|
$136,800
$18.21 P/Share
|
|
Oct 02
2025
|
William P. Burke Mr. Director |
SELL
Open market or private sale
|
Direct |
7,620
-31.12%
|
$137,160
$18.01 P/Share
|
|
Oct 02
2025
|
William P. Burke Mr. Director |
SELL
Open market or private sale
|
Indirect |
2,400
-24.0%
|
$43,200
$18.01 P/Share
|
|
Sep 16
2025
|
Erick Wayne De Vinney Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
1,137
-0.51%
|
$18,192
$16.29 P/Share
|
|
Sep 13
2025
|
Erick Wayne De Vinney Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+1.11%
|
-
|
|
Jun 10
2025
|
Joseph A. Tyndall Director |
SELL
Open market or private sale
|
Direct |
26,931
-100.0%
|
$269,310
$10.72 P/Share
|
|
Jun 10
2025
|
Joseph A. Tyndall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,586
+18.9%
|
$69,516
$6.67 P/Share
|
|
Jun 09
2025
|
William P. Burke Mr. Director |
SELL
Open market or private sale
|
Direct |
4,073
-14.26%
|
$40,730
$10.61 P/Share
|
|
Jun 09
2025
|
Amy Mc Bride Wendell Director |
SELL
Open market or private sale
|
Direct |
4,073
-4.16%
|
$40,730
$10.61 P/Share
|
|
Jun 09
2025
|
Alan M Levine Director |
SELL
Open market or private sale
|
Direct |
4,073
-9.98%
|
$40,730
$10.61 P/Share
|
|
Jun 09
2025
|
Kathy Johnson Weiler Director |
SELL
Open market or private sale
|
Direct |
4,073
-38.23%
|
$40,730
$10.61 P/Share
|
|
Jun 09
2025
|
John Johnson Director |
SELL
Open market or private sale
|
Direct |
4,073
-14.04%
|
$40,730
$10.61 P/Share
|
|
Jun 09
2025
|
Guido J Neels Director |
SELL
Open market or private sale
|
Direct |
4,073
-4.48%
|
$40,730
$10.61 P/Share
|
|
May 22
2025
|
Joseph A. Tyndall Director |
SELL
Open market or private sale
|
Direct |
20,062
-34.13%
|
$220,682
$11.2 P/Share
|
|
May 22
2025
|
Joseph A. Tyndall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,850
+26.63%
|
$77,100
$6.3 P/Share
|
|
May 19
2025
|
Joseph A. Tyndall Director |
SELL
Open market or private sale
|
Direct |
2,525
-10.07%
|
$27,775
$11.63 P/Share
|
|
Mar 19
2025
|
Erick Wayne De Vinney Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
15,111
-6.49%
|
$256,887
$17.5 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 7.5K shares |
|---|---|
| Exercise of conversion of derivative security | 107K shares |
| Open market or private sale | 130K shares |
|---|---|
| Payment of exercise price or tax liability | 59.9K shares |